ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New MRI-Guided combo therapy aims to control advanced esophageal cancer
Disease control Not yet recruitingThis study tests a personalized approach using MRI scans to guide chemoradiotherapy combined with immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The goal is to see if this tailored treatment can delay cancer progressio…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for tough esophageal cancer: YL201 drug trial launches
Disease control Not yet recruitingThis study tests a new medicine called YL201 against standard chemotherapy in 440 people with advanced esophageal cancer that has worsened after initial treatment. Participants are randomly assigned to receive either YL201 or a doctor-chosen chemo. The main goal is to see if YL20…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for tough esophageal cancer: targeted combo trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether a new combination of drugs (anlotinib plus benmelstobart) works better than the current standard treatment for advanced esophageal cancer that has certain gene mutations. About 578 adults with this cancer who have not had prior treatment will be r…
Matched conditions: ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated May 18, 2026 12:00 UTC